Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20094 vs Dulaglutide in T2D Uncontrolled on Metformin +/- SGLT2i
NCT07156539Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of olatorepatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Change in Glycated Hemoglobin (HbA1c) at 44 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
olatorepatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07156539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156539.